{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:48:26Z","timestamp":1788526106959,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["Clinical Trial Fellowship (125713)"],"award-info":[{"award-number":["Clinical Trial Fellowship (125713)"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["Clinical Trials Unit (CTUQQR-Dec22\/100002)"],"award-info":[{"award-number":["Clinical Trials Unit (CTUQQR-Dec22\/100002)"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["Sample Collection Award (CRCPSC-Jul23\/100003)"],"award-info":[{"award-number":["Sample Collection Award (CRCPSC-Jul23\/100003)"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yorkshire Cancer Research","award":["POINTER-PC (RA\/2021\/R2\/111)"],"award-info":[{"award-number":["POINTER-PC (RA\/2021\/R2\/111)"]}]},{"name":"Yorkshire Cancer Research","award":["University Clinical Academic Fellow (L389LM)"],"award-info":[{"award-number":["University Clinical Academic Fellow (L389LM)"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,11,28]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised\/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies. Based on observational studies, ENI is associated with promising metastasis-free survival (MFS) compared with SBRT and appears to result in low rates of severe late toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer is a UK multicentre, open-label, phase III randomised controlled trial, which will deliver much needed, high-quality evidence of the impact on metastatic progression from ENI compared with SBRT in patients with PCa pelvic nodal recurrence. The trial will also evaluate the long-term toxicity of 5-fraction ENI compared with a standard 20-fraction schedule. The trail will randomise 480 participants in a ratio of 2:1:1 to SBRT, 5-fraction ENI or 20-fraction ENI from 35 to 40 UK radiotherapy sites over 4 years. Coprimary endpoints are MFS at 3 years and participant-reported late bowel toxicity at 3 years. Secondary endpoints include overall survival, biochemical progression-free survival, failure-free survival, patterns of failure, participant-reported\/clinician-reported toxicity and health-related quality of life. Collection of blood and tissue samples will enable future evaluation of biomarkers of disease and toxicity and support stratification of salvage therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from NHS Health Research Authority, East of England \u2013 Cambridgeshire and Hertfordshire Research Ethics Committee (24\/EE\/0099). Trial results will be published in peer-reviewed journals and adhere to International Committee of Medical Journal Editors guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN11089334\">ISRCTN11089334<\/jats:ext-link>\n                      , registered on 23 September 2024.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095560","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T07:50:41Z","timestamp":1735199441000},"page":"e095560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) \u2013 study protocol paper for a phase III multicentre, open-label randomised controlled trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn11089334","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn11089334","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-904X","authenticated-orcid":false,"given":"Finbar","family":"Slevin","sequence":"first","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"},{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Alexander","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, UK"},{"name":"The Royal Marsden NHS Foundation Trust, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-7537","authenticated-orcid":false,"given":"Sarah R","family":"Brown","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Carter","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"},{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Clipson","sequence":"additional","affiliation":[{"name":"Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Din","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[{"name":"Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"},{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3877-3838","authenticated-orcid":false,"given":"Sean","family":"Girvan","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Hingorani","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneil","family":"Jain","sequence":"additional","affiliation":[{"name":"Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lilley","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise J","family":"Murray","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"},{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Naismith","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Noutch","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oliveira","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8096-3875","authenticated-orcid":false,"given":"Christopher J H","family":"Pagett","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Talbot","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Webster","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M","family":"Henry","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"},{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"2025121514164254000_14.12.e095560.1","unstructured":"National Cancer Registration and Analysis Service (NCRAS) . CancerData: Prostate cancer. 2018. Available: https:\/\/www.cancerdata.nhs.uk\/getdataout\/prostate [Accessed 24 Jun 2021]."},{"key":"2025121514164254000_14.12.e095560.2","unstructured":"European Association of Urology . Prostate cancer. 2022. Available: https:\/\/uroweb.org\/guideline\/prostate-cancer [Accessed 9 Feb 2023]."},{"key":"2025121514164254000_14.12.e095560.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0572"},{"key":"2025121514164254000_14.12.e095560.4","unstructured":"National Comprehensive Cancer Network . Prostate cancer. 2022. Available: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459 [Accessed 7 Jul 2022]."},{"key":"2025121514164254000_14.12.e095560.5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer","volume":"2","author":"De Visschere","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"2025121514164254000_14.12.e095560.6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2017.12.048","article-title":"Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases","volume":"199","author":"Bernstein","year":"2018","journal-title":"J Urol"},{"key":"2025121514164254000_14.12.e095560.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2025121514164254000_14.12.e095560.8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121514164254000_14.12.e095560.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.04.040"},{"key":"2025121514164254000_14.12.e095560.10","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-135"},{"key":"2025121514164254000_14.12.e095560.11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"2025121514164254000_14.12.e095560.12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bju.13510","article-title":"Toxicity and efficacy of salvage carbon 11-choline positron emission tomography\/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer","volume":"119","author":"Fodor","year":"2017","journal-title":"BJU Int"},{"key":"2025121514164254000_14.12.e095560.13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00259-018-4159-0","article-title":"Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer","volume":"46","author":"L\u00e9pinoy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025121514164254000_14.12.e095560.14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2018.12.020","article-title":"Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)","volume":"103","author":"Vaugier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121514164254000_14.12.e095560.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4"},{"key":"2025121514164254000_14.12.e095560.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"2025121514164254000_14.12.e095560.17","unstructured":"Prostate Cancer UK . PACE-nodes: a clinical trial to test a rapid form of radiotherapy. 2022. Available: https:\/\/prostatecanceruk.org\/research\/research-we-fund\/ma-ct20-005 [Accessed 19 May 2022]."},{"key":"2025121514164254000_14.12.e095560.18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121514164254000_14.12.e095560.19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","article-title":"Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer","volume":"30","author":"Murthy","year":"2018","journal-title":"Clin Oncol"},{"key":"2025121514164254000_14.12.e095560.20","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121514164254000_14.12.e095560.21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.adro.2018.12.001","article-title":"Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer","volume":"4","author":"Pinitpatcharalert","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"2025121514164254000_14.12.e095560.22","article-title":"PEARLS: A multicenter phase II\/III trial of extended field radiotherapy for androgen-sensitive prostate cancer patients with PSMA\u2010avid pelvic and para-aortic lymph nodes at presentation","volume":"40","author":"Murray","year":"2022","journal-title":"J C O"},{"key":"2025121514164254000_14.12.e095560.23","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025121514164254000_14.12.e095560.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075"},{"key":"2025121514164254000_14.12.e095560.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.08.044"},{"key":"2025121514164254000_14.12.e095560.26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672195","article-title":"Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights","volume":"11","author":"Chemi","year":"2021","journal-title":"Front Oncol"},{"key":"2025121514164254000_14.12.e095560.27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","article-title":"cfDNA methylome profiling for detection and subtyping of small cell lung cancers","volume":"3","author":"Chemi","year":"2022","journal-title":"Nat Cancer"},{"key":"2025121514164254000_14.12.e095560.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519286113"},{"key":"2025121514164254000_14.12.e095560.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6"},{"key":"2025121514164254000_14.12.e095560.30","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121514164254000_14.12.e095560.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010"},{"key":"2025121514164254000_14.12.e095560.32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-020-06911-4","article-title":"PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial","volume":"20","author":"De Bruycker","year":"2020","journal-title":"BMC Cancer"},{"key":"2025121514164254000_14.12.e095560.33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.euo.2023.09.007","article-title":"PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial","volume":"7","author":"Ost","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025121514164254000_14.12.e095560.34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:16:52Z","timestamp":1765837012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,26]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2024-095560"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095560","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}